XML 44 R23.htm IDEA: XBRL DOCUMENT
v3.20.4

Quarterly Results of Operations (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Results of Operations (Unaudited) | 15.QUARTERLY RESULTS OF OPERATIONS (UNAUDITED) Quarterly data for the years ended December 31, 2020 and 2019 consisted of the following (in thousands, except per share amounts):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Quarter Ended
​ |  | March 31 |  | June 30 |  | September 30 |  | December 31
2020 |  | ​ |  |  | ​ |  |  | ​ |  |  | ​ |
Net sales | ​ | $ | 243,525 | ​ | $ | 218,371 | ​ | $ | 243,975 | ​ | $ | 258,004
Gross profit | ​ |  | 103,784 | ​ |  | 84,216 | ​ |  | 102,014 | ​ |  | 111,163
Income (loss) from operations | ​ |  | 1,362 | ​ |  | (18,995) | ​ |  | 64 | ​ |  | 16,007
Income tax expense (benefit) | ​ |  | 1,162 | ​ |  | (3,242) | ​ |  | 825 | ​ |  | (2,133)
Net income (loss) | ​ |  | (3,154) | ​ |  | (19,058) | ​ |  | (3,009) | ​ |  | 15,378
Earnings (loss) per common share - basic | ​ |  | (0.06) | ​ |  | (0.34) | ​ |  | (0.05) | ​ |  | 0.28
Earnings (loss) per common share - diluted | ​ |  | (0.06) | ​ |  | (0.34) | ​ |  | (0.05) | ​ |  | 0.27
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2019 | ​ |  |  | ​ |  |  | ​ |  |  | ​ |  |
Net sales | ​ | $ | 238,349 | ​ | $ | 255,532 | ​ | $ | 243,049 | ​ | $ | 257,922
Gross profit | ​ |  | 104,636 | ​ |  | 111,964 | ​ |  | 104,136 | ​ |  | 111,630
Income (loss) from operations | ​ |  | 9,523 | ​ |  | 12,201 | ​ |  | (2,881) | ​ |  | (3,409)
Income tax expense (benefit) | ​ |  | 651 | ​ |  | 2,140 | ​ |  | (2,292) | ​ |  | (3,757)
Net income (loss) | ​ |  | 6,195 | ​ |  | 6,859 | ​ |  | (3,398) | ​ |  | (4,205)
Earnings (loss) per common share - basic | ​ |  | 0.11 | ​ |  | 0.12 | ​ |  | (0.06) | ​ |  | (0.08)
Earnings (loss) per common share - diluted | ​ |  | 0.11 | ​ |  | 0.12 | ​ |  | (0.06) | ​ |  | (0.08)
​ During the three months ended December 31, 2020, we recorded a partial impairment charge of $8.2 million of intangible assets from our August 2019 acquisition of STD Pharmaceutical (see Note 5). During the three months ended December 31, 2019, we recorded impairment charges of $20.5 million due to our write-off of our NinePoint note receivable and purchase option, along with a write-off of $1.6 million of accrued interest (see Note 16). Basic and diluted earnings (loss) per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly amounts may not equal the total computed for the year. ​

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration